U.S. Grants Final Approval to Novavax COVID-19 Vaccine Amid Delays and New Restrictions

In a significant development, U.S. health regulators have officially approved Novavax's COVID-19 vaccine, Nuvaxovid, after an unexpected delay. The approval comes with new restrictions on the vaccine's use, raising discussions within the medical community. Novavax sought full approval from the Food and Drug Administration (FDA), having previously received emergency use authorization for individuals aged 12 and older. Unlike mRNA vaccines from Pfizer-BioNTech and Moderna, Nuvaxovid employs different technology and had not yet achieved full approval.

The FDA initially aimed to finalize the approval process by April 1 but missed this deadline, stirring concerns about regulatory reforms under former President Donald Trump and his then-Health Secretary, which critics argue impacted the approval process. The newly approved vaccine is now authorized only for specific groups: those aged 65 and above, and individuals aged 12 to 64 with underlying health conditions such as obesity or asthma that increase COVID-19 risk.

These restrictions have prompted scrutiny, especially as vaccine skepticism remains a topic of debate. Notably, vaccine skeptics like Robert F. Kennedy Jr. have criticized regulatory decisions and promoted misinformation about vaccines, including those administered to children. His influence and skepticism have gained attention amid recent measles outbreaks, prompting renewed conversations about vaccine governance.

While the approval marks an important milestone for Novavax, the limited authorization underscores ongoing debates over vaccine safety, regulation, and public health policies. The decision emphasizes targeted use of the vaccine, focusing on vulnerable populations, amid a complex landscape of COVID-19 vaccination efforts.

[Source: https://medicalxpress.com/news/2025-05-novavax-covid-jab-delay-restrictions.html]